Quarterly ResultMay 7, 2026, 07:17 AM
Charles River Q1 Revenue $995.8M, GAAP Loss $(0.30), Divestiture Completed
AI Summary
Charles River Laboratories reported first-quarter 2026 revenue of $995.8 million, a 1.2% increase year-over-year. The company posted a GAAP diluted loss per share of $(0.30), primarily due to a $118.0 million loss on assets held for sale related to the recently completed divestiture of its CDMO and Cell Solutions businesses. Non-GAAP diluted earnings per share decreased 12.0% to $2.06. The company reaffirmed its 2026 organic revenue and non-GAAP EPS guidance and repurchased $200 million of common stock during the quarter.
Key Highlights
- Completed divestiture of CDMO and Cell Solutions businesses on May 6, 2026.
- Repurchased $200 million of common stock in Q1 2026.
- Q1 Revenue: $995.8 million, up 1.2% from Q1 2025.
- Q1 GAAP Loss per Share: $(0.30), compared to $0.50 in Q1 2025.
- Q1 Non-GAAP EPS: $2.06, down 12.0% from $2.34 in Q1 2025.
- Reaffirmed 2026 organic revenue and non-GAAP EPS guidance.
- Divestiture resulted in a $118.0 million loss on assets held for sale.
- Organic revenue declined 1.5% overall in Q1 2026.